Skip to main content

Table 3 Baseline migraine characteristics and patient function and disability for 4 age groups (efficacy groupings)

From: Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

 Migraine CharacteristicsPatient Function and Disability
 Years since diagnosisMonthly migraine headache daysMonthly migraine headache days with acute medication MSQ-RFR scorePGI-S scoreMIDAS total score
Age group (years)Treat.NMean (SD)Mean (SD)Mean (SD)NMean (SD)Mean (SD)Mean (SD)
Episodic
≤40PBO
120
240
381
219
220
14.0 (7.6)
14.2 (8.5)
14.3 (7.7)
9.3 (2.9)
9.3 (3.0)
9.2 (2.9)
6.9 (3.5)
7.1 (3.6)
7.1 (3.4)
379
219
218
52.1 (15.9)
51.8 (15.4)
48.9 (17.1)2
4.2 (1.1)1
4.2 (1.1)
4.3 (1.2)
33.1 (26.4)
29.9 (23.5)
37.9 (28.1)2
> 40 to ≤ 50PBO
120
240
298
125
113
22.0 (11.5)
23.1 (10.4)
22.4 (11.8)
9.3 (3.1)
8.9 (2.7)
9.0 (2.9)
8.2 (3.3)
7.7 (3.1)
7.8 (3.0)
296
124
111
51.6 (14.4)
51.6 (15.7)
51.5 (15.7)
4.3 (1.2)
4.4 (1.1)
4.4 (1.2)
34.0 (31.4)
35.6 (31.0)
30.4 (24.6)
> 50 to ≤ 55PBO
120
240
96
54
58
25.3 (12.8)
27.8 (12.2)
26.4 (13.1)
8.7 (3.0)
9.1 (2.9)
9.1 (3.2)
7.7 (3.5)
8.1 (3.3)
8.0 (3.3)
96
54
58
51.7 (17.1)
50.8 (16.3)
50.3 (17.3)
4.3 (1.3)
4.2 (1.4)
4.4 (1.2)
32.0 (23.1)
36.3 (38.7)
31.8 (33.7)
> 55 to ≤ 65PBO
120
240
119
46
44
34.1 (14.0)
34.8 (13.9)
30.5 (14.6)
8.7 (3.0)
8.9 (3.4)
8.8 (3.0)
7.7 (3.2)
7.5 (3.9)
7.3 (3.3)
116
46
43
54.0 (16.3)
55.3 (13.8)
54.2 (15.2)
4.2 (1.2)
4.0 (1.1)
4.3 (1.1)
31.7 (36.6)
26.0 (23.3)
30.3 (29.2)
p-value3 < 0.0010.128< 0.001 0.0750.3490.468
Chronic
≤40PBO
120
240
253
144
127
14.8 (8.2)
14.7 (8.8)
13.3 (8.2)
20.0 (4.6)
19.7 (4.2)
19.6 (4.6)
14.3 (7.1)
13.9 (6.5)
13.3 (6.2)
247
141
125
37.8 (16.7)
37.6 (17.0)
39.1 (17.1)
4.8 (1.3)
4.9 (1.2)
4.7 (1.2)
69.1 (53.6)
64.2 (51.7)
76.4 (66.6)
> 40 to ≤ 50PBO
120
240
162
75
76
24.1 (11.3)
23.6 (11.9)
21.9 (12.1)
19.4 (4.5)
19.1 (4.3)
19.1 (4.6)
16.7 (5.7)
16.0 (5.8)
15.2 (6.3)
159
75
74
37.7 (18.3)
41.0 (18.1)
37.5 (18.3)
5.1 (1.2)
4.8 (1.3)
5.0 (1.5)
76.3 (67.7)
59.3 (45.9)2
65.4 (60.8)
> 50 to ≤ 55PBO
120
240
65
31
32
28.7 (13.5)
25.8 (14.5)
24.1 (11.9)
18.9 (3.9)
18.3 (4.7)
17.4 (4.3)
15.8 (5.6)
16.0 (6.7)
13.4 (5.6)
63
29
32
38.6 (16.7)
40.9 (17.8)
38.7 (13.9)
4.9 (1.2)
4.6 (1.2)
4.9 (1.2)
63.0 (49.5)
63.3 (51.1)
60.5 (48.9)
> 55 to ≤ 65PBO
120
240
78
28
42
35.0 (12.9)
34.9 (13.6)
34.3 (11.7)
19.0 (5.2)
19.4 (4.4)
19.4 (4.6)
16.8 (6.5)
18.1 (4.0)
17.6 (5.7)
77
27
41
41.5 (16.7)
41.6 (16.4)
41.2 (18.9)
4.8 (1.3)
4.6 (1.5)
5.2 (1.4)
56.0 (49.7)
61.4 (47.5)
60.8 (71.8)
p-value3 < 0.0010.006< 0.001 0.2140.1810.128
  1. Abbreviations: 120 Galcanezumab 120 mg, 240 Galcanezumab 240 mg, MIDAS Migraine Disability Assessment, MSQ-RFR Migraine-specific quality-of-life questionnaire role function-restrictive domain, PBO Placebo, PGI-S Patient global impression of severity, SD Standard deviation, Treat Treatment
  2. 1Group included 380 patients
  3. 2p-value < 0.05 compared to PBO-treatment arm in same age group
  4. 3p-value compares overall means between age groups
\